Home » Business News » 2012 » September » September 14, 2012

PropThink: Amarin Cancels Investor Conference Appearance; Read-through Could Be Positive

September 14, 2012 -

Reports from Bloomberg that Amarin Corp. (NASDAQ:AMRN) has pulled out of the UBS Global Life Sciences Conference next week is leading some analysts to the assumption that the company has advanced talks with potential partners or acquirers of the company. AMRN management has not been shy with investors about its discussions with large-cap drug companies to potentially become a marketing partner or perhaps purchase the company outright for its lead product, Vascepa, which was approved in July. Sources say that the company is cancelling its presentation because of a self-imposed quiet period in front of the FDA's decision on Vascepa's NCE status (see PropThink's latest article), however, given that there is typically no set date for an NCE decision, investors are skeptical of this reason. Assumptions that the company has moved to advanced discussions with potential drug company partners could push shares of AMRN higher. Many analysts are calling for the company to be acquired and have an average price target for AMRN at $26 per share, suggesting that the stock has room to run if an acquisition is truly at hand.
To see this article in is original format, click here.
About PropThink
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on To learn more, follow us on Twitter or visit us at

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: PropThink via Thomson Reuters ONE


Copyright 2012 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

ACN Newswire

Comment on this story